Q-omics provides the consensus-scored SNX19P4 profile across patient tissues and cancer cell-line models. SNX19P4 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SNX19P4 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, SNX19P4 RNA expression shows 11,001 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight BLCA, and COAD as cancer lineages where SNX19P4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX19P4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX19P4 survival associations across molecular data types. SNX19P4 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX19P4 RNA expression–survival associations across cancer types. High SNX19P4 expression shows unfavorable associations in KICH, DLBC, ACC, CHOL and LIHC, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for SNX19P4 RNA expression.
This table summarizes SNX19P4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for SNX19P4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX19P4 shows lower tumor expression in COAD, LUSC and STAD and higher tumor expression in LIHC, PRAD and BRCA. The COAD box plot shows higher SNX19P4 RNA expression in normal versus tumor tissue (log2 FC = −0.596, t-test p < 0.001).
This table shows molecular features associated with SNX19P4 in patient tissues and cancer cell lines. In patient samples, SNX19P4 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set.
